In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Genmab (GMAB – Research Report). The company’s shares closed yesterday at $29.86.
According to TipRanks, Goonewardene is a 3-star analyst with an average return of 2.9% and a 35.77% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Genmab, Compugen, and Iovance Biotherapeutics.
Genmab has an analyst consensus of Moderate Buy, with a price target consensus of $39.75, representing a 33.12% upside. In a report released on April 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.
The company has a one-year high of $43.00 and a one-year low of $26.32. Currently, Genmab has an average volume of 641.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genmab (GMAB) Company Description:
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
